Multifunctional immature dental pulp stem cells and therapeutic applications

Abstract

The present invention is directed to therapeutic multifunctional immature dental pulp stem cells (IDPSCs), and IDPSCs multi-lineage compositions. The invention is further directed to the use of IDPSCs and compositions to reduce the risk of and/or treat degenerative diseases or for other medicinal and aesthetic purposes.

1 . A cryopreserved composition comprising an isolated population of IDPSCs, wherein at least 50% of the IDPSCs express a p53 tumor suppressor marker. 
     
     
         2 . The composition of  claim 1 , wherein less than 50% of the IDPSCs express a CD13 marker. 
     
     
         3 . The composition of  claim 1 , wherein less than 50% of the IDPSCs express a CD31 marker. 
     
     
         4 . The composition of  claim 1 , wherein less than 50% of the IDPSCs express a marker selected from CD13 and CD31 and the IDPSCs are negative for CD34, CD43, and CD45 markers. 
     
     
         5 . The composition of  claim 1 , wherein at least 50% of the IDPSCs produce a neurotrophic factor selected from brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GNDF), nerve growth factor-beta (beta-NGF), neurotrophin-3 (NT3), neurotrophin-4 (NT4), and neurotrophin-5 (NT5). 
     
     
         6 . (canceled) 
     
     
         7 . The composition of  claim 1 , wherein at least 75% of the IDPSCs express nestin. 
     
     
         8 . (canceled) 
     
     
         9 . The composition of  claim 1 , wherein less than 20% of the IDPSCs express Oct3/4. 
     
     
         10 . (canceled) 
     
     
         11 . A cryopreserved cell culture composition comprising human immature dental pulp stem cell (hIDPSCs) that co-express SOX-1 and SOX-2 and are neural crest stem cells. 
     
     
         12 . (canceled) 
     
     
         13 . A cryopreserved pharmaceutical formulation comprising migratory immature dental pulp stem cells (IDPSCs) expressing CD73 (ecto-5′-nucleotidase) and p53. 
     
     
         14 . The pharmaceutical formulation according to  claim 13 , wherein the IDPSCs express CD105, CD73, and CD90 and lack expression of CD45, CD34, and HLA-DR. 
     
     
         15 . The pharmaceutical formulation according to  claim 13 , wherein the IDPSCs express CD29 (integrin beta 1). 
     
     
         16 . The pharmaceutical formulation according to  claim 13 , wherein the migratory IDPSCs express OCT 4, nestin, and/or p63. 
     
     
         17 . The pharmaceutical formulation according to  claim 13 , wherein the migratory IDPSCs are in a unit dosage injectable form selected from the group consisting of a solution, a suspension, a dispersion, and an emulsion. 
     
     
         18 . The pharmaceutical formulation according to  claim 17 , wherein the unit dosage injectable form is an aqueous dispersion. 
     
     
         19 . The pharmaceutical formulation according to  claim 18 , wherein the pH of the aqueous dispersion is between about 6.8 and about 7.5. 
     
     
         20 . The pharmaceutical formulation according to  claim 18 , wherein the ionic strength of the aqueous dispersion is between about 0.1 and about 0.2. 
     
     
         21 . The pharmaceutical formulation according to  claim 13 , further comprising a fluid lubricant. 
     
     
         22 . The pharmaceutical formulation according to  claim 13 , further comprising a carrier, wherein the carrier is a solvent or a dispersing mechanism. 
     
     
         23 . (canceled) 
     
     
         24 . The pharmaceutical formulation according to  claim 22 , wherein the carrier comprises water, saline, or phosphate buffered saline. 
     
     
         25 . The pharmaceutical formulation according to  claim 13 , further comprising an additive and/or an excipient, wherein the additive and/or excipient are present in an amount of 0.001 to 50 weight percent. 
     
     
         26 - 33 . (canceled)